EPS Corporation, a Shinjuku-ku, Tokyo-based CRO, has reached an agreement to offer CluePoints’ Risk Based Quality Management (RBQM) solutions to its sponsors. The RBQM tools will complement either new or existing RBM processes through the CluePoints Central Monitoring Platform to allow EPS sponsors drive early risk detection, improve quality and enhance patient safety in clinical trials.
For the full release, click here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.